The SME initial public offering (IPO) of New Delhi-headquartered healthcare logistics, cold-chain phlebotomy, and diagnostic supply chain major Credent Connect N Care Limited (operating under its commercial brand C3 Logistics) officially locked its bidding windows today, Monday, August 17, 2026.

Following an exceptional buildup across Day 1 (2.18x) and Day 2 (12.12x), the final afternoon recorded an extraordinary multi-category institutional, wealth, and retail capital avalanche. By the drop of the terminal shutters at 5:00 PM IST across the NSE SME platform, central exchange matching engines compiled valid electronic application tokens for 50,71,67,400 equity shares against a net public offer pool of 33,12,000 equity shares (excluding anchor allocations and the market maker quota).

This pushed the final overall subscription level to a massive 153.13 times.

Priced within a fixed band parameter of ₹179 to ₹189 per share with a total issue size of ₹93.90 crore, the offering mobilized an aggregate primary capital demand value of ₹9,585.46 crore (~₹9.59 Thousand Crore) clearing through central registries.

With bidding officially completed, investor attention now turns directly to final allotment probabilities, unlisted grey market trends, subsidiary and working capital deployment, and the upcoming stock exchange debut scheduled for Thursday, August 20, 2026.

Here is an extended, plain-English human breakdown covering final subscription metrics, business operations under C3 Logistics, financial performance, grey market numbers, and the upcoming allotment schedule.

1. Final Subscription Data: Category-by-Category Breakdown

By 5:00 PM on Day 3, central processing systems compiled valid application tokens for 50,71,67,400 equity shares against the net offered size of 33,12,000 equity shares.

At the upper price band limit of ₹189 per share, this represents an aggregate primary demand value of ₹9,585.46 crore.

The table below breaks down final demand metrics across all investor categories:

+-----------------------------------------------------------------------------------+
|               CREDENT CONNECT N CARE LIMITED: FINAL SUBSCRIPTION DATA             |
+-------------------+-----------------+------------------+------------------+-------+
| Category          | Shares Offered  | Shares Bid For   | Final Sub (x)    | Value |
+-------------------+-----------------+------------------+------------------+-------+
| QIB (Institutions)| 9,48,000        | 12,36,15,600     | 130.40x          | ₹2,336.3Cr
| NII / HNI (Wealth)| 7,08,000        | 15,36,15,000     | 216.97x          | ₹2,903.3Cr
| Retail (RII)      | 16,56,000       | 22,99,36,800     | 138.85x          | ₹4,345.8Cr
| Market Maker      | 2,52,000        | —                | —                | —     |
+-------------------+-----------------+------------------+------------------+-------+
| Total Net Offer   | 33,12,000       | 50,71,67,400     | 153.13x          | ₹9,585.5Cr
+-------------------+-----------------+------------------+------------------+-------+

Analyzing the Final Category Inflows:

  • Non-Institutional Investors (NII / HNI - 216.97x): High-net-worth wealth accounts and family offices spearheaded the final-day volume surge, advancing from 9.73x on Day 2 to an extraordinary 216.97 times. HNI applicants submitted electronic orders for 15.36 crore shares worth ₹2,903.32 crore. Both big-HNI (bidding above ₹10 lakh) and small-HNI (bidding between ₹2 lakh and ₹10 lakh) brackets saw massive multi-lot application volumes.
  • Retail Individual Investors (RII - 138.85x): Everyday retail accounts maintained heavy application momentum throughout the day, moving from 16.39x on Day 2 to close at 138.85 times. Retail participants placed bids for 22.99 crore shares (1,91,614 application lots) worth ₹4,345.81 crore. Under the issue rules, retail applicants faced a minimum lot requirement of 2 lots (1,200 shares), requiring an upfront layout of ₹2,26,800 at ₹189 per share.
  • Qualified Institutional Buyers (QIB - 130.40x): Institutional funds stepped in heavily on the final afternoon, taking their category from 6.45x on Day 2 to 130.40 times. Institutional desks submitted bids for 12.36 crore shares worth ₹2,336.33 crore.
  • Anchor Investor Allocation: Prior to the public open, Credent Connect N Care raised ₹26.54 crore through its institutional anchor placement on Wednesday, August 12, 2026. A total of 14,04,000 shares were allocated to marquee anchor investors at ₹189 per share, including Sunil Singhania's Abakkus Venture Opportunities Fund, Motilal Oswal Finvest, Hem Growth Opportunities Fund, Mint Focussed Growth Fund, and 360 ONE LVF Treasury Solutions Fund.
  • Market Maker Block: A dedicated block of 2,52,000 shares (~₹4.76 crore) is allocated to the designated market maker (Hem Finlease Private Limited) to provide secondary market liquidity support post-listing.

2. Unlisted Grey Market Premium (GMP) & Expected Listing Gains

With final bidding figures locked in at 153.13x overall coverage, sentiment in the unlisted grey market corridors has stayed firmly positive:

  • Fixed Upper Price Cap Anchor: ₹189.00 per share
  • Current Grey Market Premium (GMP): Tracking around +₹55.00 per share (~29.1% over issue price)
  • Estimated Listing Price Range: Expected debut counter level of ₹244.00 per share
  • Projected Listing Gain Margin: Indicating an immediate estimated listing upside of ~29.10%
  • Retail Application Lot Size: 2 Lots / 1,200 Shares (Minimum Investment: ₹2,26,800)

What Is Driving Grey Market Optimism?

  1. Critical Specialized Healthcare Infrastructure: Cold-chain biological sample transit is a high-barrier business. Diagnostic chains cannot risk temperature spikes that ruin blood samples, giving established B2B players like Credent long-term contract stickiness.
  2. High Top-Line Scaling & ROE: Revenue from operations reached ₹214.16 crore in FY26, supporting a Return on Net Worth (RoNW) above 42%.

(Note: Grey market premiums represent informal, off-exchange quotes traded among dealers. They move based on daily market mood and should not be treated as a guaranteed listing price.)

3. Business Overview: What Does Credent Connect N Care Do?

Incorporated in June 2015 and headquartered in New Delhi, Credent Connect N Care Limited is an integrated B2B healthcare services, temperature-controlled logistics, and phlebotomy workforce solutions provider.

Operating under its commercial brand C3 Logistics, the company serves as a vital operational platform for diagnostic laboratories, In-Vitro Diagnostic (IVD) equipment manufacturers, pharmaceutical companies, hospitals, clinics, and corporate healthcare enterprises across India.

+-----------------------------------------------------------------------------------+
|                  CREDENT CONNECT N CARE BUSINESS AT A GLANCE                      |
+-----------------------------------+-----------------------------------------------+
| Commercial Operating Brand        | C3 Logistics, C3 Wellness & C3 Post           |
+-----------------------------------+-----------------------------------------------+
| Core Service Pillars              | Cold-Chain Diagnostic Sample Transit, Doorstep|
|                                   | Phlebotomy, Reagent Movement, Paramedic Staffing|
+-----------------------------------+-----------------------------------------------+
| B2B Client Ecosystem Depth        | Associated with 2,500+ Diagnostic Labs,       |
|                                   | IVD Companies, Hospitals & Pharma Majors      |
+-----------------------------------+-----------------------------------------------+
| Operational Field Workforce       | 6,500+ Trained Field Professionals &          |
|                                   | Temperature-Controlled Phlebotomy Personnel   |
+-----------------------------------+-----------------------------------------------+
| Pan-India Network Reach           | Operating across 452+ Cities & Towns in India |
+-----------------------------------+-----------------------------------------------+
| Primary Geographic Footprint      | Maharashtra (29.4%), UP (26.8%), Delhi (10.9%)|
+-----------------------------------+-----------------------------------------------+

(Source: Official Red Herring Prospectus & Issue Filings)

Core Competitive Moats:

1. High-Barrier Temperature-Controlled Cold Chain

Transporting blood, tissue, and biological specimens requires strict temperature maintenance (e.g., 2°C to 8°C or frozen below -20°C). Credent deploys IoT-enabled active cold boxes with real-time temperature telemetry. If temperature fluctuates during transit, automated alerts trigger re-icing protocols, ensuring sample integrity before reaching central testing hubs.

2. Pan-India Phlebotomy & Last-Mile Field Force

With over 6,500 trained phlebotomists and field executives spanning 452+ cities, Credent handles doorstep home sample collection, stationed hospital phlebotomy, and corporate wellness health checkups. Diagnostic chains outsource home collection to Credent to avoid managing thousands of distributed on-field employees directly.

3. Deep Integration with Major Diagnostic Chains

Serving more than 2,500 laboratories and healthcare institutions creates high switching costs. Once a diagnostic network connects its central LIS (Laboratory Information System) software to Credent's logistics API for daily sample pickup routes, changing vendors risks logistical disruption and Turnaround Time (TAT) delays.

4. Detailed Financial Performance (FY24 to FY26)

An audit of Credent Connect N Care's restated consolidated financial statements reveals rapid top-line expansion alongside expanding operational and net profit margins over the last three fiscal years.

+-----------------------------------------------------------------------------------+
|               CREDENT CONNECT N CARE: 3-YEAR FINANCIAL PERFORMANCE                |
+-------------------------------+-------------------+-------------------+-----------+
| Financial Metric (₹ in Cr)    | FY24              | FY25              | FY26      |
+-------------------------------+-------------------+-------------------+-----------+
| Revenue from Operations       | 42.15             | 77.94             | 214.16    |
| Total Income                  | 42.28             | 78.10             | 214.43    |
| Operating EBITDA              | 2.85              | 4.99              | 28.46     |
| EBITDA Margin (%)             | 6.76%             | 6.40%             | 13.29%    |
| Net Profit After Tax (PAT)    | 1.82              | 3.61              | 18.45     |
| PAT Margin (%)                | 4.30%             | 4.62%             | 8.60%     |
| Total Debt / Borrowings       | 8.12              | 12.45             | ~24.50    |
| Net Worth                     | 11.20             | 16.85             | 48.20     |
| Return on Net Worth (RoNW %)  | 19.51%            | 14.13%            | 42.13%    |
+-------------------------------+-------------------+-------------------+-----------+

(Source: Restated Consolidated Financial Statements in RHP & KPI Reports)

Key Financial Observations:

  1. Explosive Top-Line Scaling: Operating revenue expanded from ₹42.15 crore in FY24 to ₹77.94 crore in FY25, before surging 174.8% YoY to ₹214.16 crore in FY26. Growth was driven by subsidiary consolidation, expanding B2B operations, supply chain management, and higher phlebotomy sample collection volumes.
  2. EBITDA & Net Profit Surge: Operating EBITDA jumped from ₹4.99 crore in FY25 to ₹28.46 crore in FY26 (EBITDA margin expanding to 13.29%), while net profit after tax (PAT) jumped from ₹3.61 crore to ₹18.45 crore (PAT margin expanding to 8.60%). Higher revenue density across existing cold-chain transit routes boosted operating leverage.
  3. High Return on Net Worth: Capital efficiency improved significantly, pushing the company's Return on Net Worth (RoNW) to 42.13% in FY26.

5. Structure of the Offer & Objects of the Issue

The ₹93.90 crore public offer is structured entirely as a fresh capital issue:

+-----------------------------------------------------------------------------------+
|                         IPO CAPITAL STRUCTURE BREAKDOWN                           |
+-----------------------------------+-----------------------------------------------+
| Total Issue Size                  | ₹93.90 Crore (49,68,000 Equity Shares)        |
+-----------------------------------+-----------------------------------------------+
| Fresh Issue Component             | ₹93.90 Crore (100% Fresh Capital Issue)       |
+-----------------------------------+-----------------------------------------------+
| Offer for Sale (OFS) Component    | ₹0.00 (No Selling Shareholders)               |
+-----------------------------------+-----------------------------------------------+
| Price Band                        | ₹179 to ₹189 per share                        |
+-----------------------------------+-----------------------------------------------+
| Face Value                        | ₹10 per share                                 |
+-----------------------------------+-----------------------------------------------+
| Market Maker Reserved Block       | 2,52,000 Shares (₹4.76 Crore Value)           |
+-----------------------------------+-----------------------------------------------+
| Lead Manager (BRLM)               | Hem Securities Limited                        |
+-----------------------------------+-----------------------------------------------+
| Registrar to the Issue            | KFin Technologies Limited                     |
+-----------------------------------+-----------------------------------------------+

(Source: Official Issue Prospectus)

How Will the Fresh Primary Capital Be Spent?

Because there is no Offer for Sale (OFS), 100% of the net proceeds will move directly onto the company balance sheet. Credent Connect N Care has earmarked the net proceeds for four primary areas:

  1. Working Capital Financing (₹37.00 Crore / 39.4%): Healthcare logistics and staffing solutions involve extended payment credit cycles from diagnostic chains and hospital networks. Infusing working capital will support cash flow requirements as revenues scale.
  2. Investment in Operating Subsidiaries (₹29.80 Crore / 31.7%): Injected into Credent Healthcare Private Limited to fund its working capital (₹26.80 crore) and machinery CAPEX (₹3.00 crore).
  3. Debt Repayment / Prepayment (₹6.00 Crore / 6.4%): Paying down existing bank term loans and borrowings, reducing annual interest overheads.
  4. General Corporate Purposes & Issue Expenses (₹21.10 Crore / 22.5%): Supporting administrative run-rates, tech infrastructure upgrades, and issue management fees.

6. Valuation Analysis & Peer Group Comparison

At the upper price band cap of ₹189 per share, Credent Connect N Care is priced at a trailing Price-to-Earnings (P/E) multiple of 13.58x on pre-issue equity and 18.68x based on post-issue diluted capital, establishing a post-issue corporate market capitalization of approximately ₹344.41 crore.

Let's compare this with listed logistics, healthcare support, and diagnostic service providers in India:

+-----------------------------------------------------------------------------------+
|                        PEER GROUP VALUATION COMPARISON                            |
+-----------------------------------+--------------------+--------------------------+
| Company Name                      | Trailing P/E (x)   | Primary Focus / Model    |
+-----------------------------------+--------------------+--------------------------+
| Credent Connect N Care (At ₹189)  | ~18.68x (Post-IPO) | Healthcare Logistics & B2B|
| Delhivery Limited                 | ~2.45x (P/S)       | Third-Party Logistics    |
| TCI Express Ltd                   | ~28.50x            | Express Cold Logistics   |
| Krsnaa Diagnostics Ltd            | ~36.50x            | PPP Diagnostic Support   |
| Metropolis Healthcare Ltd         | ~54.30x            | Diagnostic Testing Chain |
+-----------------------------------+--------------------+--------------------------+

(Source: Peer Comparison Data from Official Prospectus & KPI Filings)

Valuation Summary:

At 18.68x post-issue FY26 trailing earnings, Credent Connect N Care entered the market at a disciplined valuation structure compared to diagnostic testing chains (36x–54x P/E) and express logistics players (~28.5x P/E).

With revenue scaling past ₹214 crore, a 42.13% RoNW, and a 100% fresh issue structure, the reasonable multiple provided a strong fundamental margin of safety that drove the massive 153x subscription surge.

7. Core Strengths vs. Key Business Risks

Investors tracking post-allotment developments should consider the following operational factors:

Key Strengths:

  • Historic 153.13x Final Demand Validation: Mobilizing over ₹9,585 crore in primary demand reflects exceptional market conviction.
  • Massive 216.97x HNI & 130.40x QIB Demand: Solid participation across both institutional and wealth categories.
  • 100% Fresh Issue Structure: No promoter cash-out; all ₹93.90 crore raised goes into subsidiary investment, working capital, and debt reduction.
  • Blue-Chip Institutional Anchor Book: Sunil Singhania's Abakkus, Motilal Oswal Finvest, and 360 ONE anchor participation provided strong early validation.

Key Risk Factors:

  • Customer Concentration Risk: The company's top 10 clients contributed over 80% of total revenue in FY26. Losing any key diagnostic chain partner could affect sales volumes.
  • Working Capital Intensity & Trade Receivables: B2B healthcare contracts carry high trade receivables, making cash flows sensitive to customer payment credit cycles.
  • Operational Transit Risks: Moving biological samples requires strict handling; temperature spikes or delays can lead to contamination claims.

8. Allotment Architecture & Final Listing Timeline

With bidding officially completed today, here is the upcoming schedule for allotment finalization and stock exchange listing:

  • Bidding Window Close Date: Monday, August 17, 2026 (Status: Bidding Closed)
  • Basis of Allotment Finalization: Tuesday, August 18, 2026
  • Refund Initiations & Unblocking of Bank Funds: Wednesday, August 19, 2026
  • Credit of Equity Shares to Demat Accounts: Wednesday, August 19, 2026
  • Official Stock Exchange Listing (NSE Emerge / SME): Thursday, August 20, 2026
  • Designated Registrar: KFin Technologies Limited

How to Check Your Allotment Status:

When allotment details go live on Tuesday, August 18, 2026, applicants can check their status by entering their PAN card number or Application ID on the KFintech IPO Status Portal or directly on the official NSE website under the SME allotment section.

Conclusion

Credent Connect N Care has concluded its public offering with a massive 153.13x overall subscription (~₹9,585 crore total demand), driven by 216.97x HNI demand, 138.85x retail interest, and 130.40x QIB coverage.

With ₹93.90 crore in fresh capital moving into subsidiary expansion and working capital, an established cold-chain presence across 452+ cities, 42.13% RoNW returns, and an 18.68x post-issue P/E entry valuation, the company is set for its NSE SME exchange debut on Thursday, August 20.

Post Excerpt

A complete final day analysis of Credent Connect N Care Ltd’s IPO closing books. Overall subscription surged to 153.13x, led by an extraordinary 216.97x HNI surge, 138.85x retail demand, and 130.40x QIB coverage. Includes a full review of company financials, C3 Logistics cold-chain moats, grey market trends (+₹55), allotment schedule, and valuation comparison ahead of its August 20 debut.